{"entity":{"id":"mario-campone","kind":"person","name":"Mario Campone","aka":[],"tldr":"Medical oncologist who is Director General of the Institut de Cancérologie de l'Ouest, the regional cancer centre for western France with sites in Angers and Nantes.","summary":"Professor Mario Campone is Directeur Général of the Institut de Cancérologie de l'Ouest (ICO), the Centre de Lutte Contre le Cancer for the Pays de la Loire region, which operates from two sites, in Angers and in Saint-Herblain near Nantes, with its registered office in Angers. The institute's own presentation page lists him as Directeur Général and as a consultative member of the Conseil d'Administration, alongside a published governance charter. The French Wikipedia article on the institute likewise states that it is directed by Professor Campone. Neither source gives his appointment date.","asOf":"2026-09-10","links":[{"label":"Source: ICO institutional page naming the Directeur Général","url":"https://www.institut-cancerologie-ouest.com/linstitut-de-cancerologie-de-louest"},{"label":"Source: Wikipedia (French), Institut de cancérologie de l'Ouest","url":"https://fr.wikipedia.org/wiki/Institut_de_canc%C3%A9rologie_de_l%27Ouest"}],"tags":["leadership","clinician-scientist","comprehensive-cancer-centre"],"related":[],"cancers":["breast-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["ico-angers-nantes"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Directeur Général (Director General), Institut de Cancérologie de l'Ouest","institutionId":"ico-angers-nantes","specialisms":["Medical oncology","Breast cancer","Cancer centre management"],"profiles":[{"label":"ICO institutional presentation page","url":"https://www.institut-cancerologie-ouest.com/linstitut-de-cancerologie-de-louest"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Campone+M%5BAuthor%5D"}],"papers":[{"title":"Pathological complete response after neoadjuvant chemotherapy is an independent predictive factor irrespective of simplified breast cancer intrinsic subtypes: a landmark and two-step approach analyses from the EORTC 10994/BIG 1-00 phase III trial","journal":"Annals of Oncology","year":2014,"doi":"10.1093/annonc/mdu118"},{"title":"UCBG 2-08: 5-year efficacy results from the UNICANCER-PACS08 randomised phase III trial of adjuvant treatment with FEC100 and then either docetaxel or ixabepilone in patients with early-stage, poor prognosis breast cancer","journal":"European Journal of Cancer","year":2018,"doi":"10.1016/j.ejca.2018.06.025"},{"title":"Phase I study of emactuzumab single agent or in combination with paclitaxel in patients with advanced/metastatic solid tumors reveals depletion of immunosuppressive M2-like macrophages","journal":"Annals of Oncology","year":2019,"doi":"10.1093/annonc/mdz163"}]},"route":"/people/mario-campone/","neighbours":{"cancer":[{"id":"breast-cancer","kind":"cancer","name":"Breast cancer (all types)","route":"/cancers/breast-cancer/"}],"institution":[{"id":"ico-angers-nantes","kind":"institution","name":"Institut de Cancérologie de l'Ouest (ICO)","route":"/institutions/ico-angers-nantes/"}]}}